Medicare Enrolled
Dr. Michael Poiesz, M.D.
Hematology & Oncology · Pensacola, FL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Poiesz from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Poiesz?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Poiesz
Dr. Michael Poiesz is a hematology & oncology specialist in Pensacola, FL, with 18 years of NPI registration. Based on federal Medicare data, Dr. Poiesz performed 115,071 Medicare services across 2,290 unique beneficiaries.
Between the years covered by Open Payments, Dr. Poiesz received a total of $3,296 from 45 pharmaceutical and/or device companies across 170 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Poiesz is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice
▲ Top 6% volume in FL
$3,296 industry payments
Florida License Status
FL DOH · MQA1
Active license
None
Board action on record
0
Recent admin complaints
| Profession | License # | Status | Expires | Board Action |
|---|---|---|---|---|
| Medical Doctor | 120309 | Clear | January 31, 2028 | — |
Data from Florida Department of Health Medical Quality Assurance.
License records are public under Chapter 119, Florida Statutes.
Verify directly on FL DOH →
Medicare Practice Summary
Medicare Utilization ↗115,071
Medicare services
Top 6% in FL for hematology & oncology
2,290
Unique beneficiaries
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~6,393 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Filgrastim injection (Nivestym) for white blood cells An injection of the biosimilar medication filgrastim-aafi (Nivestym) at a dose of 1 microgram. |
30,180 | $0 | $2 |
| Pembrolizumab injection (Keytruda) | 19,400 | $43 | $131 |
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
16,320 | $0 | $6 |
| Paclitaxel chemotherapy injection | 9,138 | $0 | $1 |
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
9,050 | $2 | $21 |
| Contrast dye for imaging (iodine-based) A contrast agent containing 300-399 mg/ml of iodine used to enhance imaging studies. It is administered per milliliter to improve the visibility of internal structures. |
5,600 | $0 | $3 |
| Anti-nausea injection (aprepitant) | 5,070 | $1 | $8 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
4,200 | $0 | $6 |
| Iron infusion (Monoferric) | 3,600 | $16 | $71 |
| Denosumab injection (Prolia/Xgeva) | 2,280 | $18 | $46 |
| Immune globulin infusion (Octagam) This procedure involves the administration of immune globulin medication directly into a vein. It is provided in a non-lyophilized liquid form. |
1,800 | $34 | $221 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,302 | $93 | $224 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,242 | $0 | $1 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
920 | $6 | $30 |
| Anti-nausea injection (Aloxi/palonosetron) | 890 | $1 | $122 |
| Injection, granisetron hydrochloride, 100 mcg | 580 | $0 | $25 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
425 | $12 | $105 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
372 | $2 | $300 |
| Pegfilgrastim-apgf injection An injection of pegfilgrastim-apgf, a biosimilar medication. The dose specified is 0.5 mg. |
372 | $93 | $157 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
281 | $100 | $686 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
253 | $11 | $93 |
| Gadobenate dimeglumine injection Administration of gadobenate dimeglumine, a contrast agent used to enhance imaging results. |
170 | $1 | $16 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
150 | $65 | $148 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
121 | $22 | $152 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
107 | $48 | $304 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
107 | $50 | $334 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
103 | $129 | $343 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
98 | $1 | $5 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
94 | $22 | $156 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
89 | $134 | $301 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
75 | $4 | $26 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
74 | $16 | $97 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
69 | $55 | $205 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 61 | $409 | $638 |
| Nuclear medicine scan from skull base to mid-thigh with CT A nuclear medicine imaging study covering the area from the base of the skull to the middle of the thighs, performed alongside a CT scan. |
57 | $1,208 | $4,120 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
54 | $6 | $462 |
| CT scan of chest with contrast A computed tomography scan of the chest using a contrast dye to enhance the visibility of internal structures. |
37 | $97 | $1,005 |
| Blood creatinine level test A blood test that measures the amount of creatinine, a waste product from muscle wear and tear, to help assess kidney function. |
35 | $5 | $30 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
30 | $24 | $141 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
30 | $1 | $19 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
28 | $43 | $281 |
| CT scan of chest, without contrast A computed tomography scan of the chest area that uses X-rays to create detailed images without the use of contrast dye. |
25 | $83 | $861 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
24 | $19 | $111 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
23 | $140 | $412 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
20 | $19 | $64 |
| CT scan of abdomen and pelvis with contrast A CT scan that uses dye to create detailed images of the abdomen and pelvis. This imaging test helps doctors examine internal organs and structures in these areas. |
19 | $228 | $1,400 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
19 | $25 | $249 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
19 | $27 | $240 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
18 | $57 | $157 |
| Digital breast tomosynthesis (3D mammogram) A specialized imaging test that creates three-dimensional pictures of the breast tissue to help detect abnormalities. |
16 | $42 | $226 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
13 | $89 | $297 |
| New patient office visit, complex (60-74 min) | 11 | $138 | $432 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
19.5% high complexity
78.9% medium
1.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$3,296
Total received (2018-2024)
Avg $471/year across 7 years
Bottom 44% in FL for hematology & oncology
45
Companies
170
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,972 (90.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$323 (9.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$300
2023
$377
2022
$341
2021
$231
2020
$28
2019
$447
2018
$1,572
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$391
PFIZER INC.
$343
E.R. Squibb & Sons, L.L.C.
$259
Astellas Pharma US Inc
$255
Janssen Biotech, Inc.
$249
Ipsen Biopharmaceuticals, Inc
$234
Celgene Corporation
$112
Merck Sharp & Dohme Corporation
$101
Amgen Inc.
$92
AstraZeneca Pharmaceuticals LP
$88
GENZYME CORPORATION
$83
Genentech USA, Inc.
$81
Janssen Scientific Affairs, LLC
$79
Mirati Therapeutics, Inc.
$78
Daiichi Sankyo Inc.
$57
Pharmacyclics LLC, An AbbVie Company
$52
ABBVIE INC.
$50
Alexion Pharmaceuticals, Inc.
$47
Boston Scientific Corporation
$43
Sumitomo Pharma America, Inc.
$43
Lilly USA, LLC
$43
Regeneron Healthcare Solutions, Inc.
$39
TerSera Therapeutics LLC
$38
Myovant Sciences Inc.
$33
Boehringer Ingelheim Pharmaceuticals, Inc.
$31
Seattle Genetics, Inc.
$29
Lexicon Pharmaceuticals, Inc.
$27
Incyte Corporation
$27
Seagen Inc.
$26
CSL Behring
$26
EMD Serono, Inc.
$25
Kite Pharma, Inc.
$22
Stemline Therapeutics Inc.
$21
Tempus AI, Inc
$21
Eisai Inc.
$21
Adaptive Biotechnologies Corporation
$18
BeiGene USA, Inc.
$18
MEDIVATION FIELD SOLUTIONS LLC
$13
SpringWorks Therapeutics, Inc.
$13
R-Pharm US LLC
$13
Teva Pharmaceuticals USA, Inc.
$12
Exelixis Inc.
$12
Epizyme, Inc.,
$12
Kyowa Kirin, Inc.
$11
Janssen Pharmaceuticals, Inc
$9
Top 3 companies account for 30.1% of total payments
Associated products mentioned in payments ›
ADCETRIS · Afstyla · Aranesp · BENDEKA · BOSULIF · BRUKINSA · Balversa · Bavencio · CABLIVI · CEREZYME · CYRAMZA · Cabometyx · DARZALEX · Erleada · Fabhalta · GAUCHER-DISEASE · GAZYVA · GILOTRIF · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · Ixempra · JADENU · JAKAFI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · Lenvima · MEKINIST · MYLOTARG · Neulasta · OCREVUS · OGSIVEO · OPDIVO · ORGOVYX · Onivyde · Orserdu · PLUVICTO · PROMACTA · Perjeta · Pomalyst · REBLOZYL · RYDAPT · Revlimid · SANCUSO · SOLIRIS · SUTENT · Somatuline Depot · TAGRISSO · TASIGNA · TAXOTERE · TAZVERIK · TECENTRIQ · VENCLEXTA · VOTRIENT · WATCHMAN · WATCHMAN Access System · XALKORI · XT CDX · XTANDI · Xermelo · Xtandi · ZOLADEX · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (90%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $3 per 100 Medicare services performed
Geographic Context
Hematology & oncology specialists within 10 mi
20
Per 100K population
6.2
County median income
$65,715
Nearest hospital
BAPTIST HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Poiesz is a mixed practice specialist, with above-average Medicare volume (top 6% in FL), with low-engagement industry engagement, with 18 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Poiesz experienced with filgrastim injection (nivestym) for white blood cells?
Based on Medicare claims data, Dr. Poiesz performed 30,180 filgrastim injection (nivestym) for white blood cells services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Poiesz receive payments from pharmaceutical companies?
Yes. Dr. Poiesz received a total of $3,296 from 45 companies across 170 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Poiesz's costs compare to other hematology & oncology specialists in Pensacola?
Dr. Poiesz's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Poiesz) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Pensacola
Browse hematology & oncology specialists in Pensacola ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in FL
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in FL
Which FL hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology